Financhill
Sell
37

PLX Quote, Financials, Valuation and Earnings

Last price:
$2.68
Seasonality move :
2.69%
Day range:
$2.43 - $2.55
52-week range:
$0.82 - $2.76
Dividend yield:
0%
P/E ratio:
121.00x
P/S ratio:
4.32x
P/B ratio:
5.70x
Volume:
631.7K
Avg. volume:
697.6K
1-year change:
70.75%
Market cap:
$184.8M
Revenue:
$65.5M
EPS (TTM):
-$0.16

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PLX
Protalix BioTherapeutics
$18.7M -- 73.62% -- $14.50
AIM
AIM ImmunoTech
$100K -$0.09 -23.08% -53.85% $2.75
ARMP
Armata Pharmaceuticals
$1.6M -$0.35 -- -36.36% --
CATX
Perspective Therapeutics
$297.8K -$0.25 -- -40.08% $15.61
ELMD
Electromed
$15.3M -- 11.77% -- --
XTNT
Xtant Medical Holdings
$31.8M -$0.02 11.16% -33.33% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PLX
Protalix BioTherapeutics
$2.51 $14.50 $184.8M 121.00x $0.00 0% 4.32x
AIM
AIM ImmunoTech
$0.15 $2.75 $9.6M -- $0.00 0% 41.33x
ARMP
Armata Pharmaceuticals
$1.99 -- $72M -- $0.00 0% 720.95x
CATX
Perspective Therapeutics
$3.14 $15.61 $212.2M -- $0.00 0% 16.96x
ELMD
Electromed
$29.20 -- $247M 40.56x $0.00 0% 4.56x
XTNT
Xtant Medical Holdings
$0.59 -- $81.4M -- $0.00 0% 0.68x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PLX
Protalix BioTherapeutics
-- 1.876 -- 1.22x
AIM
AIM ImmunoTech
48.41% 0.854 17.25% 0.71x
ARMP
Armata Pharmaceuticals
-- 3.526 -- --
CATX
Perspective Therapeutics
-- -3.617 -- --
ELMD
Electromed
-- 2.128 -- 4.99x
XTNT
Xtant Medical Holdings
43.2% 0.590 37.09% 0.81x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PLX
Protalix BioTherapeutics
$9.6M $4M -19.69% -29.54% 23.06% $4M
AIM
AIM ImmunoTech
$27K -$4.5M -219.06% -256.33% -9994.29% -$3.3M
ARMP
Armata Pharmaceuticals
-- -$9.8M -- -- -- -$9.2M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
ELMD
Electromed
$11.5M $1.9M 15.62% 15.62% 13.21% $2.3M
XTNT
Xtant Medical Holdings
$16.3M -$3.8M -22.96% -35.98% -13.47% -$3.8M

Protalix BioTherapeutics vs. Competitors

  • Which has Higher Returns PLX or AIM?

    AIM ImmunoTech has a net margin of 18.02% compared to Protalix BioTherapeutics's net margin of -10571.43%. Protalix BioTherapeutics's return on equity of -29.54% beat AIM ImmunoTech's return on equity of -256.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    PLX
    Protalix BioTherapeutics
    53.37% $0.03 $32.4M
    AIM
    AIM ImmunoTech
    77.14% -$0.06 $5.6M
  • What do Analysts Say About PLX or AIM?

    Protalix BioTherapeutics has a consensus price target of $14.50, signalling upside risk potential of 477.69%. On the other hand AIM ImmunoTech has an analysts' consensus of $2.75 which suggests that it could grow by 1728.46%. Given that AIM ImmunoTech has higher upside potential than Protalix BioTherapeutics, analysts believe AIM ImmunoTech is more attractive than Protalix BioTherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PLX
    Protalix BioTherapeutics
    0 0 0
    AIM
    AIM ImmunoTech
    1 0 0
  • Is PLX or AIM More Risky?

    Protalix BioTherapeutics has a beta of 0.747, which suggesting that the stock is 25.306% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of -0.292, suggesting its less volatile than the S&P 500 by 129.237%.

  • Which is a Better Dividend Stock PLX or AIM?

    Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PLX or AIM?

    Protalix BioTherapeutics quarterly revenues are $18M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Protalix BioTherapeutics's net income of $3.2M is higher than AIM ImmunoTech's net income of -$3.7M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 121.00x while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 4.32x versus 41.33x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PLX
    Protalix BioTherapeutics
    4.32x 121.00x $18M $3.2M
    AIM
    AIM ImmunoTech
    41.33x -- $35K -$3.7M
  • Which has Higher Returns PLX or ARMP?

    Armata Pharmaceuticals has a net margin of 18.02% compared to Protalix BioTherapeutics's net margin of --. Protalix BioTherapeutics's return on equity of -29.54% beat Armata Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PLX
    Protalix BioTherapeutics
    53.37% $0.03 $32.4M
    ARMP
    Armata Pharmaceuticals
    -- -$0.15 --
  • What do Analysts Say About PLX or ARMP?

    Protalix BioTherapeutics has a consensus price target of $14.50, signalling upside risk potential of 477.69%. On the other hand Armata Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 251.76%. Given that Protalix BioTherapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than Armata Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    PLX
    Protalix BioTherapeutics
    0 0 0
    ARMP
    Armata Pharmaceuticals
    0 0 0
  • Is PLX or ARMP More Risky?

    Protalix BioTherapeutics has a beta of 0.747, which suggesting that the stock is 25.306% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.738%.

  • Which is a Better Dividend Stock PLX or ARMP?

    Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PLX or ARMP?

    Protalix BioTherapeutics quarterly revenues are $18M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Protalix BioTherapeutics's net income of $3.2M is higher than Armata Pharmaceuticals's net income of -$5.5M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 121.00x while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 4.32x versus 720.95x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PLX
    Protalix BioTherapeutics
    4.32x 121.00x $18M $3.2M
    ARMP
    Armata Pharmaceuticals
    720.95x -- -- -$5.5M
  • Which has Higher Returns PLX or CATX?

    Perspective Therapeutics has a net margin of 18.02% compared to Protalix BioTherapeutics's net margin of --. Protalix BioTherapeutics's return on equity of -29.54% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PLX
    Protalix BioTherapeutics
    53.37% $0.03 $32.4M
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About PLX or CATX?

    Protalix BioTherapeutics has a consensus price target of $14.50, signalling upside risk potential of 477.69%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.61 which suggests that it could grow by 411.15%. Given that Protalix BioTherapeutics has higher upside potential than Perspective Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Perspective Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    PLX
    Protalix BioTherapeutics
    0 0 0
    CATX
    Perspective Therapeutics
    7 1 0
  • Is PLX or CATX More Risky?

    Protalix BioTherapeutics has a beta of 0.747, which suggesting that the stock is 25.306% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.220, suggesting its more volatile than the S&P 500 by 22.033%.

  • Which is a Better Dividend Stock PLX or CATX?

    Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PLX or CATX?

    Protalix BioTherapeutics quarterly revenues are $18M, which are larger than Perspective Therapeutics quarterly revenues of --. Protalix BioTherapeutics's net income of $3.2M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 121.00x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 4.32x versus 16.96x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PLX
    Protalix BioTherapeutics
    4.32x 121.00x $18M $3.2M
    CATX
    Perspective Therapeutics
    16.96x -- -- -$15.1M
  • Which has Higher Returns PLX or ELMD?

    Electromed has a net margin of 18.02% compared to Protalix BioTherapeutics's net margin of 10.05%. Protalix BioTherapeutics's return on equity of -29.54% beat Electromed's return on equity of 15.62%.

    Company Gross Margin Earnings Per Share Invested Capital
    PLX
    Protalix BioTherapeutics
    53.37% $0.03 $32.4M
    ELMD
    Electromed
    78.34% $0.16 $41.5M
  • What do Analysts Say About PLX or ELMD?

    Protalix BioTherapeutics has a consensus price target of $14.50, signalling upside risk potential of 477.69%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 13.01%. Given that Protalix BioTherapeutics has higher upside potential than Electromed, analysts believe Protalix BioTherapeutics is more attractive than Electromed.

    Company Buy Ratings Hold Ratings Sell Ratings
    PLX
    Protalix BioTherapeutics
    0 0 0
    ELMD
    Electromed
    0 0 0
  • Is PLX or ELMD More Risky?

    Protalix BioTherapeutics has a beta of 0.747, which suggesting that the stock is 25.306% less volatile than S&P 500. In comparison Electromed has a beta of 0.334, suggesting its less volatile than the S&P 500 by 66.566%.

  • Which is a Better Dividend Stock PLX or ELMD?

    Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PLX or ELMD?

    Protalix BioTherapeutics quarterly revenues are $18M, which are larger than Electromed quarterly revenues of $14.7M. Protalix BioTherapeutics's net income of $3.2M is higher than Electromed's net income of $1.5M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 121.00x while Electromed's PE ratio is 40.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 4.32x versus 4.56x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PLX
    Protalix BioTherapeutics
    4.32x 121.00x $18M $3.2M
    ELMD
    Electromed
    4.56x 40.56x $14.7M $1.5M
  • Which has Higher Returns PLX or XTNT?

    Xtant Medical Holdings has a net margin of 18.02% compared to Protalix BioTherapeutics's net margin of -17.98%. Protalix BioTherapeutics's return on equity of -29.54% beat Xtant Medical Holdings's return on equity of -35.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    PLX
    Protalix BioTherapeutics
    53.37% $0.03 $32.4M
    XTNT
    Xtant Medical Holdings
    58.37% -$0.04 $80.5M
  • What do Analysts Say About PLX or XTNT?

    Protalix BioTherapeutics has a consensus price target of $14.50, signalling upside risk potential of 477.69%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 284.09%. Given that Protalix BioTherapeutics has higher upside potential than Xtant Medical Holdings, analysts believe Protalix BioTherapeutics is more attractive than Xtant Medical Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    PLX
    Protalix BioTherapeutics
    0 0 0
    XTNT
    Xtant Medical Holdings
    0 0 0
  • Is PLX or XTNT More Risky?

    Protalix BioTherapeutics has a beta of 0.747, which suggesting that the stock is 25.306% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.871%.

  • Which is a Better Dividend Stock PLX or XTNT?

    Protalix BioTherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Protalix BioTherapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PLX or XTNT?

    Protalix BioTherapeutics quarterly revenues are $18M, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Protalix BioTherapeutics's net income of $3.2M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Protalix BioTherapeutics's price-to-earnings ratio is 121.00x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Protalix BioTherapeutics is 4.32x versus 0.68x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PLX
    Protalix BioTherapeutics
    4.32x 121.00x $18M $3.2M
    XTNT
    Xtant Medical Holdings
    0.68x -- $27.9M -$5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Will Palantir Stock Be Worth in 2030?
What Will Palantir Stock Be Worth in 2030?

Palantir Technologies (NYSE: PLTR) has emerged from a growth slowdown…

Is Rollins Stock a Buy, Sell or Hold?
Is Rollins Stock a Buy, Sell or Hold?

Pest control giant Rollins (NYSE:ROL) is the parent company of…

Why Did Bill Ackman Buy Uber?
Why Did Bill Ackman Buy Uber?

In early 2025, billionaire investor Bill Ackman, CEO of Pershing…

Stock Ideas

Buy
59
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 111x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
65
ATEX alert for Feb 12

Anterix [ATEX] is down 0.72% over the past day.

Buy
87
GDS alert for Feb 12

GDS Holdings [GDS] is up 0.32% over the past day.

Sell
30
SPSC alert for Feb 12

SPS Commerce [SPSC] is up 0.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock